Tepotinib: Management of Adverse Events in Patients With MET Exon 14 Skipping Non-Small Cell Lung Cancer.
Sign Up to like & getrecommendations! Published in 2022 at "Clinical journal of oncology nursing"
DOI: 10.1188/22.cjon.543-551
Abstract: BACKGROUND Tepotinib, a highly selective, oral, once-daily MET inhibitor, has been approved for treatment of metastatic MET exon 14 skipping non-small cell lung cancer. OBJECTIVES This article provides nurse-specific recommendations for identification and management of… read more here.
Keywords: non small; skipping non; small cell; met exon ... See more keywords